Baseline characteristics of patients

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

Trial profile Fox K et al. Lancet 2008;372:

analysis from the SHIFT study

Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Participant Characteristics by Lowest Leg AAI Category Ann M. O’Hare, et al, Circulation 2006;113;

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

Table 1. Baseline Characteristics of the 36,636 Study Subjects

LEADER trial: Primary Outcome

Volume 385, Issue 9985, Pages (June 2015)

Copyright © 2006 American Medical Association. All rights reserved.

Copyright © 2007 American Medical Association. All rights reserved.

Copyright © 2009 American Medical Association. All rights reserved.

TNT: Baseline and final LDL cholesterol levels

Trial profile John A Dormandy et al. Lancet 2005;366:

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Relative risk of major events with atenolol vs placebo

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Significance of Periprocedural Myocardial Infarctions in Percutaneous Coronary Interventions A New Look at an Old Topic Abhiram Prasad, MD, FRCP, FESC,

Mintu P. Turakhia et al. JACEP 2016;2:

Volume 385, Issue 9985, Pages (June 2015)

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Svend A. Mortensen et al. JCHF 2014;2:

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Baseline Characteristics by Baseline N-BNP Level

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Shannon M. Dunlay, MD, MS, Quinn R. Pack, MD, Randal J

Collet JP, et al. Lancet 2009;373:309-17

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Baseline Characteristics of the Patients – Part I

Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus James H. O'Keefe, MD, Mohammad Abuannadi,

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Kaplan-Meier curve of cumulative percentage of cardiac mortality by peak flow rate category (adjusted HRs (95% CI) compared with ≥550 L/min: (

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

Comparison of Baseline Characteristics by Primary End Point

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Associations between type of MI and incident HF

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Kaplan-Meier survival estimates for major cardiovascular events.

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Increase of physical activity over time associated with lower HF risk

Characteristics of 3415 patients admitted to hospital with

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Risk for cardiovascular disease and all-cause death according to RHR: (A) as categorical variable (HR≥75 bpm vs HR

Orly Vardeny et al. JCHF 2016;4:

Left Ventricular Mass at MRI and Long-Term Risk of Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis (MESA) Left ventricular hypertrophy.

Prevalence of acute myocardial infarction (AMI) or other cardiovascular events (CVEs) according to the presence of acute respiratory failure (ARF) and.

Identification of thresholds for significant renal recovery in relation to patient and renal survival. Identification of thresholds for significant renal.

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Baseline characteristics of patients Fox K et al. Lancet 2008;372:817-21

Adjusted hazard ratios (HR), 95% CIs, and p values for elevated resting heart rate at baseline and as a continuous variable for cardiovascular mortality and morbidity Fox K et al. Lancet 2008;372:817-21

Kaplan-Meier time-to-event plots split by heart rate for (A) cardiovascular death, (B) admission to hospital for heart failure, (C) admission to hospital for myocardial infarction, and (D) coronary revascularisation Fox K et al. Lancet 2008;372:817-21

Crude event rates and hazard ratios according to heart rate group Crude event rates (bars; left-hand scale) and hazard ratios (and 95% CI; right-hand scale) according to heart rate group relative to heart rate of less than 65 bpm for (A) cardiovascular death, (B) admission to hospital for heart failure, (C) admission to hospital for myocardial infarction, and (D) coronary revascularisation Fox K et al. Lancet 2008;372:817-21